A Sinovac Biotech Ltd. minority investor fighting for a $600 million dividend and board changes at the vaccine company is entitled to an order requiring controlling shareholders to make several disclosures, a federal court ruled.
The allegedly controlling stock owners must file “an amended and accurate Schedule 13D with the SEC disclosing their beneficial ownership interests, control relationships, group affiliations, and plans/proposals relating to Sinovac,” the US District Court for the District of Massachusetts said Monday. The submission to the Securities and Exchange Commission must be made within five days, Judge Myong J. Joun said.
The defendants are Sinovac’s new ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.